Clinical Trials Directory

Trials / Completed

CompletedNCT06341127

Fluoxetine in KCNC1-related Disorder

A Single Patient Trial of Fluoxetine in KCNC1-related Disorder

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
1 (actual)
Sponsor
Holland Bloorview Kids Rehabilitation Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a single patient study of oral powdered fluoxetine to target developmental outcomes in a child with KCNC1-related disorder. This trial will be conducted at Holland Bloorview Kids Rehabilitation Hospital over 32 to 42 weeks, using a quasi experimental ABA phase design (placebo-fluoxetine-placebo) with randomized and blinded active treatment start and stop moments.

Conditions

Interventions

TypeNameDescription
DRUGFluoxetineOral fluoxetine daily, 2.5 to 5 mg.

Timeline

Start date
2024-01-17
Primary completion
2024-11-28
Completion
2024-11-28
First posted
2024-04-02
Last updated
2025-07-02

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT06341127. Inclusion in this directory is not an endorsement.